China Biologic Products Holdings Inc (NASDAQ:CBPO) has been given a consensus rating of “Hold” by the seven research firms that are currently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $105.00.

CBPO has been the subject of a number of analyst reports. Zacks Investment Research downgraded China Biologic Products from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 9th. Credit Suisse Group downgraded China Biologic Products from an “outperform” rating to a “neutral” rating in a research note on Monday, August 6th. BidaskClub downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research note on Saturday, August 18th. Finally, ValuEngine downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research note on Friday, August 24th.

Several institutional investors have recently bought and sold shares of the business. Baillie Gifford & Co. lifted its position in shares of China Biologic Products by 0.7% during the 2nd quarter. Baillie Gifford & Co. now owns 1,347,282 shares of the biopharmaceutical company’s stock worth $133,826,000 after buying an additional 8,968 shares in the last quarter. BlackRock Inc. lifted its position in shares of China Biologic Products by 36.5% during the 1st quarter. BlackRock Inc. now owns 926,412 shares of the biopharmaceutical company’s stock worth $75,038,000 after buying an additional 247,555 shares in the last quarter. Bank of America Corp DE lifted its position in shares of China Biologic Products by 19.8% during the 2nd quarter. Bank of America Corp DE now owns 651,261 shares of the biopharmaceutical company’s stock worth $64,690,000 after buying an additional 107,573 shares in the last quarter. FMR LLC lifted its position in shares of China Biologic Products by 0.3% during the 2nd quarter. FMR LLC now owns 234,100 shares of the biopharmaceutical company’s stock worth $23,253,000 after buying an additional 700 shares in the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of China Biologic Products by 10.7% during the 2nd quarter. Renaissance Technologies LLC now owns 123,600 shares of the biopharmaceutical company’s stock worth $12,277,000 after buying an additional 11,900 shares in the last quarter. 44.22% of the stock is currently owned by hedge funds and other institutional investors.

CBPO stock opened at $74.59 on Friday. The stock has a market cap of $2.65 billion, a price-to-earnings ratio of 15.07, a P/E/G ratio of 1.66 and a beta of 1.19. China Biologic Products has a 52-week low of $71.85 and a 52-week high of $107.44.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings results on Friday, August 3rd. The biopharmaceutical company reported $1.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.26 by ($0.09). The company had revenue of $120.40 million for the quarter, compared to analyst estimates of $116.21 million. China Biologic Products had a net margin of 15.89% and a return on equity of 14.00%. China Biologic Products’s revenue for the quarter was up 34.8% on a year-over-year basis. During the same quarter last year, the firm posted $1.35 EPS. Equities research analysts expect that China Biologic Products will post 3.71 earnings per share for the current fiscal year.

China Biologic Products Company Profile

China Biologic Products Holdings, Inc engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in the People's Republic of China. It offers human albumin for treating shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; and neonatal hyperbilirubinemia, as well as for the prevention and treatment of low-density-lipoproteinemia.

Featured Article: Bond

Receive News & Ratings for China Biologic Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products and related companies with MarketBeat.com's FREE daily email newsletter.